

CURRICULUM VITAE
Melhem M. Solh, M.D.

Blood & Marrow Transplant Group of Georgia
5670 Peachtree Dunwoody Rd, Suite 1000
Atlanta, GA 30342
Phone: 404 0255-1930 **Cell:** 404 333-2083
Fax: 678 538-1718 **Email:** msolh@bmtga.com

Work Experience

July 2011-8/2014	Assistant Professor of Medicine, University of Central Florida
July 2011-2014	Florida Center for Cellular Therapy, Adult Bone Marrow Transplant Physician
June 2012-2014	Medical Director, Florida Hospital Cellular Therapy Laboratory
June 2012-2014	Clinical Director, Florida Center for Cellular Therapy
Sept 2014- 2019	Physician, Blood & Marrow Transplant Group of Georgia
Jan 2019-Present	Partner, Blood and Marrow Transplant Group of Georgia
Jan 2021-present	Medical Director Cellular Therapy Program Northside Hospital Cancer Institute

EDUCATION

June 1999	American University of Beirut, Beirut, Lebanon Bachelor of Science in Chemistry
June 2003	American University of Beirut, Beirut, Lebanon Doctor of Medicine

POSTDOCTORAL TRAINING

June 2004	American University of Beirut Medical Center, Beirut, Lebanon Rotating Internship
June 2005	Providence Hospital and Clinics, Southfield, Michigan Preliminary Internship General Surgery
June 2008	Wayne State University, Detroit Medical Center (Grace Hospital), Residency Internal Medicine
June 2011	University of Minnesota Medical Center, Minneapolis, MN Fellowship Hematology, Oncology and Transplantation

CERTIFICATION AND LICENSURE

Medical Licensure

2011-2014 State of Florida [# ME 109528]
2014-Present State of GA [#71637]

Certification

2008 American Board of Internal Medicine
2011 American Board of Hematology
2011 American Board of Oncology

HONORS AND AWARDS

1996-1999 Dean's Honor List, American University of Beirut, Faculty of Arts and Sciences
2001 Dean's Honor List, American University of Beirut, School of Medicine
2003 Dean's Honor List, American University of Beirut, School of Medicine
2005 International College of Surgeons, Third Place Poster Award
2005 Providence Hospital and Clinics Department of Surgery, Best Research of the Year
2006 Wayne State University (DMC) Sinai Grace Research Day, Oral Clinical Research Presentation, Second Place
2006 Wayne State University (DMC) Sinai Grace Research Day, Oral Basic Science Research Presentation, First Place
2006 Wayne State University (DMC), Best Intern of the Year
2006 American College of Physicians Scientific Meeting, Traverse City, Michigan, Oral Research Presentation, First Place
2007 Wayne State University (DMC), Best Resident of the Year
2007 Wayne State University (DMC) Sinai Grace Research Day, Oral Clinical Research Presentation, Second Place
2007 American College of Physicians Annual Meeting, San Diego, Poster, First Place Research Award
2007 American College of Physicians Associate Meeting, Michigan, Poster Clinical Research Presentation, First Place
2008 American College of Physicians Associate Meeting, Michigan, Oral Clinical Research Presentation, First Place
2019, 2020,2021 Castle Connolly Top Doctor award
2019, 2020,2021 Atlanta Magazine Atlanta Top Doctors

ACTIVITIES / COMMITTEES

2003	American University of Beirut School of Medicine, Student Representative Committee, President
2009	University of Minnesota Medical Center, Blood Course Teaching Committee
2011-2014	Florida Hospital Institutional Review Board
2012-Present	Foundation for the Accreditation for Cellular Therapy (FACT), Inspector
2013-2015	FACT Program Relations Committee
2011-Present	Reviewer for Journals: BMT, BBMT, Leukemia Research, American Journal of Hematology, Blood, Leukemia, Leukemia Lymphoma, Cancer
2018-present	Leukemia Lymphoma Society Annual Meeting Organizing Committee
2020-Present	Chair, Atlanta Multiple Myeloma Symposium
2020-Present	Chair, Southeast Lymphoma Symposium
2021-Present	MDS Protocol Writing Committee American Society of Cellular Therapy
2021-Present	Chair, Heme Malignancy Steering Committee, Northside Hospital Cancer Institute

PROFESSIONAL SOCIETIES

2005-2008	American College of Physicians
2008-Present	American Society of Oncology
2008-Present	American Society of Hematology
2008-Present	American Society of Bone Marrow Transplantation
2015-Present	Georgia Society of Clinical Oncology

PUBLICATIONS

Peer-Reviewed Publications

1. Chaiyasate, K., **Solh M**, S. Silapaswan, and V. Mittal. Intussusception after Roux-en-Y gastrojejunostomy: sequela of the Roux stasis syndrome? Surgical Rounds, June:2006.

2. **Solh M.**, M. Sabir, L. Dubay, and F. Minhas. Adenocystic breast cancer. *Surgical Rounds*, June:2006
3. Danquah, G., V. Mittal, **Solh M**, and R. B. Kolachalam. Effect of Internet use on patient's surgical outcomes. *International Surgery*, 92:339-343, 2007.
4. Bu-Ali, H, **Solh M**, A. Kapur, and V. Mittal. Receptor characteristics of the second tumor in synchronous versus metachronous breast cancer. *American Surgeon*, 74:702-706, 2008
5. **Solh M**, Appel J. Tumor Lysis Syndrome. *Hospital physician*, 44 (9), 2008
6. **Solh M**, Arat M, Majhail N, Weisdorf D. Late Onset Non-infectious Pulmonary Complications Post allogeneic Transplant. *Transplantation*. 2011 Apr 15; 91(7):798-803
7. **Solh M**, Brunstein C, Morgan S, Weisdorf D. Platelet and Red blood Cell Utilization and Transfusion Independence in Umbilical Cord Blood and Allogeneic Peripheral Blood Hematopoietic Cell Transplants. *Biol Blood and Marrow Transplant*. 2011 May;17(5):710-6
8. **Solh M**, Zantek N, Datta Y. Acquired Glanzmann's Thrombasthenia with Optimal response to Rituximab. *American J of Hematology*. 2011 Aug; 86(8):715-6.
9. **Solh M**, Weisdorf D, Kaufman D. Extramedullary Relapse of AML after Allogeneic HCT: better Prognosis than Systemic Relapse. *BBMT*. 2012 Jan 18; 18(1): 106-112
10. **Solh M**, Majhail N, Burns L. A Prognostic index that predicts survival among mechanically Ventilated HCT recipients. *BBMT*. Sep 2012;18(9): 1378-1384
11. **Solh M**, Rai K, Peterson B, Tallman M, Larson R, Morrison V. The Impact of Fludarabine Therapy on Transformation to Richter's Syndrome or PLL in Patients with CLL: Analysis of Intergroup Trial (CALGB 9011). *Leuk Lymphoma*. 2013 Feb; 54(2):252-254
12. Khaled Y, Alhazouri Ahmed, Reddy V, **Solh M**. Stem Cell Mobilization in Heavily Pretreated Multiple Myeloma patients with Prior High Dose Melphalan and Autologous Stem Cell Transplantation . *BMT* Feb 2013, 48(2) 310-11
13. **Solh M**, Fisher RI, Devos A, Bernstein SH, Esseltine DL, Neuwirth R, Morrison VA. Herpes Zoster Complicating Bortezomib Therapy of Relapsed/Refractory Indolent B-Cell and Mantle Cell lymphoma. *Leukemia Lymphoma* 2013, Oct; 54(10):2185-9
14. Ajaz B, Akhtar A, Chang CC, **Solh M**, Khaled Y. Plasma Cell CD20 Expression: Primary Aberrant Expression or Receptor Upregulation. *Leuk Lymphoma*. 2014 Feb; 55(2):444-6
15. Kapur LH, Khaled YK, **Solh M**, Chang CC. De novo CD3 negative hepatosplenic T-Cell lymphoma: diagnostic challenges and pitfalls. *Arch Pathol Lab Med*. 2014 July; 138(7):969-73
16. Hamadani M, Hari PN, Zhang Y, Carerras J, **Solh M**, Waller Ek. Early failure of Frontline Rituximab-containing Chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. *BBMT* 2014 Nov, 20(11):1729-36

17. **Solh M**, Yohe S, Weisdorf D, Ustun C. Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring and therapy. *Am J Haematol*. 2014 Dec; 89(12):1121-31
18. **Solh M**. Haploidentical vs cord blood transplantation for adults with acute myelogenous leukemia. *World J Stem Cells* 2014 Sep 26;6(4):371-9
19. Hogan F, **Solh M**. Autoimmune demyelinating polyneuropathy as a manifestation of chronic graft versus host disease after adult cord blood transplantation in a patient with CLL. *Case Rep Hematol*. 2014:758094
20. Arai S, Arora M, **Solh M**, Pavletic SZ. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. *BBMT* 2015 Feb;21(2):266-74
21. Batista A, Lamontagne D, **Solh M**. Processing the 5-ml umbilical cord blood unit with the use of an automated wash procedure. *Cytotherapy* 2015 Mar;17(3):336-7
22. Oyer JL, Igarashi R, **Solh M**, Copik AJ. Generation of highly cytotoxic natural killer cells for treatment of AML using a feeder free, particle-based approach. *BBMT* 2015 April; 21(4):632-9
23. Inamoto Y, Flowers ME, Wang T, **Solh M**, et al. Tacrolimus versus cyclosporine after hematopoietic cell transplantation for acquired aplastic anemia. *BBMT* 2015 Oct; 21(10):1776-82
24. Solh T, Botsford A, **Solh M**. Glanzmann's thrombasthenia: pathogenesis, diagnosis and current and emerging treatment options. *J Blood Med* 2015 July 8;6:219-27
25. LaPorte J, **Solh M**, Ouanounou S. Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed hodgkin's lymphoma. *Journal of Clinical Practice*. 2015 Dec 11
26. Bashey A, Zhang X, Jackson K, Brown S, Ridgeway M, **Solh M** et al. Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors using post-transplant cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A multivariable Analysis Including Disease Risk Index. *BBMT* 2016;Jan22(1):125-133
27. **Solh M**, Shanley R, Mc Cullough J, Weisdorf D. Blood transfusions and pulmonary complications following hematopoietic cell transplantation. *Transfusion*. 2016 Mar;56(3):653-61
28. Solomon S, **Solh M**, Morris LE, Holland HK, Bashey A. Myeloablative conditioning with PBSC grafts for T-cell replete haploidentical donor transplantation using posttransplant cyclophosphamide. *Hindawi Publishing, Advances in Hematology*. Volume 2016, Article ID 9736564. 7 pages. <http://dx.doi.org/10.1155/2016/973664>.
29. Oyer JL, Pandey V, Igarashi RY, Somanchi SS, Zakari A, **Solh M**, Lee DA, Altomare DA, Copik AJ. NK cells stimulated with PM21 particles expand and biodistribute in vivo: clinical implications for cancer treatment. *Cytotherapy*. 2016 May;18(5):653-63
30. **Solh M**, Zhang X, Conner K, Brown S, Solomon SR, Morris LE, Holland HK, Bashey A. Post relapse survival (PRS) after haploidentical transplantation

- (HIDT) versus matched related (MRD) or matched unrelated (MUD) hematopoietic cell transplantation (HCT). *BBMT*. 2016 Jul;51(7):949-54
31. **Solh M**, Solomon S, Morris LE, Holland HK, Bashey A. Extramedullary acute myelogenous leukemia. *Blood Rev*. 2016. At press. 2016 Sept;30(5):333-9
 32. **Solh M**, Zhang X, Conner K, Brown S, Solomon SR, Morris LE, Holland HK, Bashey A. Factors predicting graft-versus-host-disease-free. Relapse-free Survival after allogeneic hematopoietic cell transplantation: Multivariable Analysis from a single center, *BBMT*. 2016 Aug;22(8):1403-1409
 32. Gorgeis J, Zhang X, Connor K, Brown S, Solomon SR, Morris LE, Holland HK, Bashey A, **Solh M**. T-cell replete HLA-haploidentical donor transplantation (HIDT) with post-transplant cyclophosphamide (PTCY) is an effective salvage For patients relapsing after an HLA-matched related (MRDT) or a matched Unrelated donor transplantation (MUDT). *BBMT*. 2016 Oct;22(10):1861-6

 33. Solomon S, Sizemore CA, Zhang X, Brown S, Holland HK, Morris LE, **Solh M**, Bashey A. Impact of donor type on outcome after allogeneic hematopoietic cell transplantation for acute leukemia. *BBMT*. 2016 Oct 22;(10):1816-22.
 34. Gerds A, Woo a, Hu Z, Abdel Azim H, Akpek G Aljurf M, Ballen K, Beitinjaneh A, Bacher U, Cahn J, Chhabra S, Cutler C, Daly A, Deflipp Z, Gale R, Gergis U Grunwald M, Hale G, Hamilton B, Jagasia M, Kamble R, Kindwall-Keller T, Nishihori T, Olsson R, Ramanathan M, Saad A, **Solh M**. Ustun C, Valcarcel D, Warlick E, Wirk B, Kalaycio M, Alyea E, Popat U, Sobecks R, Saberr W. Outcomes after umbilical cord blood transplantation for myelodysplastic Syndrome. *BBMT*. 2017 June;23(6):971-79
 35. Khoury H, Wang T, Hemmer M, Couriel D, Alousi A, Cutler C, Aljurf M, Antin J, Ayas M, Battiwalla M, Cahn J, Cairo M, Chen Y, Gale R, Hashmi S, Hayashi R, Jagasia M, Juckett M, Kamble R, Kharfan-Dabaja M, Litzow M, Majhail N, Miller A, Nishihori T, Qayed M, Schoeman H, Schouten H, Socie G, Storek J, Verdonck L, Vij R, Wood WA Yu L, Martino R, Carabasi M, Dandoy C, Gergis U. Hematti P, **Solh M**, Jamani K, Lehmann L, Savani B, Schultz K, Wirk B, Spellman S, Arora M, Pidala J. Improved Survival after acute graft-versus-host disease diagnosis in modern era. *Haematologica*. 2017 May;102(5): 958-66.
 36. Solomon SR, Sizemore C, Zhang X, Ridgeway M, **Solh M**, Morris LE, Holland HK, Bashey A Current Graft-versus-host disease free, relapse free survival: A dynamic Endpoint to better define efficacy after allogeneic transplant. *BBMT* 2017 Jul;23(7):1208-1214.
 37. Bashey A, Zhang M, Mccurdy S St. Martin A, Argall T, Ciurea S, Fasan O, Gaballa S, Hamadani M, Munshi P, Al Malki M, Nakamura R, O'donnell P, Pereles M, Raj K, Romee R, Rowley S, Rocha V, Salit R, **Solh M**, Soiffer R, Fuchs E, Eapen M. Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell replete haploidentical donor using post-transplant cyclophosphamide. *JCO*. 2017 Sep10;35(26):3002-9
 38. **Solh M**, Zhang X, Connor K, Brown S, Morris LE, Holland HK, Bashey A,

- Solomon S. Donor type and disease risk predict the success of allogeneic Hematopoietic cell transplantation: a single center analysis of 613 adult Hematopoietic cell transplantation recipients using a modified composite Endpoint. *BBMT*. 2017 Dec;23(12):2192-2198.
39. Solomon SR, Aubrey MT, Zhang X, Piluso A, Freed BM, Brown S, Jackson KC, Morris LE, Holland HK, **Solh M**, Bashey A. Selecting the best donor for haploidentical transplant: Impact of HLA Killer cell immunoglobulin-like receptor genotyping and other clinical variables. *BBMT* 2018 Apr24(4):789-798
 40. Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM, Ahmed S, Inwards D, Aljurf M, Chen AI, Choe H, Cohen J, Copelan E, Farooq U, Fenske TS, Freytes C, Gaballa S, Ganguly S, Jethava Y, Kamble RT, Kenkre VP, Lazarus H, Lazaryan A, Olsson RF, Rezvani AR, Rizzieri D, Seo S, Shah GL, Shah N, **Solh M**, Sureda A, William B, Cumpston A, Zelenetz AD, Link BK, Hamadani M. Autologous Transplant in Follicular Lymphoma with early therapy failure: A national lymphocare study and center for international blood and marrow transplant research analysis. *BBMT* 2017 Dec 11(17). Epub ahead of print.
 41. **Solh MM**, Bashey A, Solomon SR, Morris LE, Zhang X, Brown S, Holland HK. Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients. *Bone marrow transplant* 2018 May;53(5):576-583
 42. Solomon SR, Zhang X, Holland HK, Morris LE, **Solh M**, Bashey A. Superior survival of black versus white patients following post-transplant cyclophosphamide based haploidentical transplantation for adults with hematologic malignancy. *Biol Blood Marrow Transplant*. 2018 Feb 13.. [Epub ahead of print]
 43. Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Ahmed I, Beitinjaneh A, Buchbinder D, Byrne M, Callander N, Chao N, Choi SW, DeFilipp Z, Gadalla SM, Gale RP, Gergis U, Hashmi S, Hematti P, Holmberg L, Inamoto Y, Kamble RT, Lehmann L, MacMillan MA, McIver Z, Nishihori T, Norkin M, O'Brien T, Olsson RF, Reshef R, Saad A, Savani BN, Schouten HC, Seo S, **Solh M**, Verdonck L, Vij R, Wirk B, Yared J, Horowitz MM, Knight JM, Verneris MR. Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. *Bone Marrow Transplant*. 2018 Jan 30 [Epub ahead of print]
 44. McCurdy SR, Zhang MJ, St Martin A, Al Malki MM, Bashey A, Gaballa S, Keesler DA, Hamadani M, Norkin M, Perales MA, Reshef R, Rocha V, Romee R, **Solh M**, Urbano-Ispizua A, Waller EK, Fuchs EJ, Eapen M. Effect of donor characteristics on haploidentical transplantation with posttransplant cyclophosphamide. *Blood Adv*. 2018 Feb 13;2(3):299-307
 45. Bashey ZA, Zhang X, Brown S, Jackson K, Morris LE, Holland HK, Bashey A, Solomon SR, **Solh M**. Comparison of outcome following transplantation with T replete HLA haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older. *Bone Marrow Transplant*. 2018 Mar 9. [Epub ahead of print]

46. Kumar AJ, Kim S, Hemmer MT, Arora M, Spellman SR, Pidala JA, Couriel DR, Alousi AM, Aljurf MD, Cahn JY, Cairo MS, Cutler CS, Farhan S, Gergis U, Hale GA, Hashmi SK, Inamoto Y, Kamble RT, Kharfan-Dabaja MA, MacMillan ML, Marks DI, Nakasone H, Norkin M, Qayed M, Ringden O, Schouten HC, Schultz KR, **Solh MM**, Teshima T, Urbano-Ispizua A, Verdonck LF, Gale RP, Hamilton BK, Majhail NS, Loren AW. Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. *Blood Adv.* 2018 May 8;2(9):1022-1031
47. A unique schedule of palonosetron, ondansetron, and dexamethasone for the prevention of delayed nausea and vomiting in patients receiving myeloablative chemotherapy. LaPorte J, Leone K, Zhang X, Holland K, Morris L, Bashey A, Solh M, Solomon SJ. *Oncol Pharm Pract.* 2018 Jul 29;1078155218790345.
48. Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. Scott EC, Hari P, Kumar S, Fraser R, Davila O, Shah N, Gale RP, Diaz MA, Agrawal V, Cornell RF, Ganguly S, Akpek G, Freytes C, Hashmi S, Malek E, Kamble RT, Lazarus H, **Solh M**, Usmani SZ, Kanate AS, Saad A, Chhabra S, Gergis U, Cerny J, Kyle RA, Lee C, Kindwall-Keller T, Assal A, Hildebrandt GC, Holmberg L, Maziarz RT, Nishihori T, Seo S, Kumar S, Mark T, D'Souza A. *Biol Blood Marrow Transplant.* 2018 Dec;24(12):2443-2449. doi:
49. Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. Norkin M, Shaw BE, Tecca HR, Solh M, Marks DI et al. *Biol Blood Marrow Transplant.* 2019 Feb; 25(2):362-368
50. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Chhabra S, Ahn KW, Hu ZH, Jain S, Assal A, Cerny J, Copelan EA, Daly A, DeFilipp Z, Gadalla SM, Gale RP, Ganguly S, Hamilton BK, Hildebrandt GC, Hsu JW, Inamoto Y, Kanate AS, Khoury HJ, Lazarus HM, Litzow MR, Nathan S, Olsson RF, Pawarode A, Ringden O, Rowe JM, Saad A, Savani BN, Schouten HC, Seo S, Shah NN, Solh M, Stuart RK, Ustun C, Woolfrey AE, Yared JA, Alyea EP, Kalaycio ME, Popat U, Sobecks RM, Saber W. *Blood Adv.* 2018 Nov 13;2(21):2922-2936.
51. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P. *Biol Blood Marrow Transplant.* 2019 Apr;25(4):683-688
52. Chimeric Antigen Receptor T-Cells: The Future is Now. Mchayleh W, Bedi P, Sehgal R, Solh M. *J Clin Med.* 2019 Feb 7;8(2). pii: E207
53. Solh M, Zhang Xu, Solomon SR, Morris LE, Holland K, Bashey A. The dilemma of conditioning intensity: When does myeloablative conditioning improve

- outcomes for allogeneic hematopoietic cell transplantation? *Bone Marrow Transplant.* Mar 2019; 25(3):606-612
54. **Solh M**, Dickhause E, Morris LE, Bashey A, Solomon SR, Holland H. Fevers post Infusion of T replete HLA mismatched Haploidentical hematopoietic stem cells. *BBMT* 2019 Apr 5 Epub ahead of print.
 55. Solomon SR, **Solh M**, Zhang Xu, Holland K, Morris LE, Bashey A. Safety and efficacy of rituximab based first line treatment of chronic GVHD. *Bone Marrow Transplant.* 2018 Dec 5
 56. Chabbara S, Hemmer M, Pidala J, Alousi A, **solh M**, Dennis K, Majhail N, Macmillan M. Comparative analysis of calcineurin-inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of Graft-versus-Host Disease after Reduced Intensity Conditioning allogeneic transplantation. *Biol Blood Marrow Transplant.* 2019 Jan;25(1):73-85
 57. GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Ahmed I, Aljurf M, Askar M, Auletta JJ, Bhatt V, Bredeson C, Chhabra S, Gadalla S, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Inamoto Y, Kitko C, Khandelwal P, MacMillan ML, Majhail N, Marks DI, Mehta P, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Qayed M, Rangarajan H, Ringden O, Saad A, Savani BN, Seo S, Shah A, Shah N, Schultz KR, Solh M, Spitzer T, Szer J, Teshima T, Verdonck LF, Williams KM, Wirk B, Wagner J, Yared JA, Weisdorf DJ. *Blood Adv.* 2019 May 14;3(9):1441-1449.
 58. Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. Saad A, Lamb L, Wang T, Hemmer MT, Spellman S, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Agrawal V, Aljurf M, Beitinjaneh AM, Bhatt VR, Buchbinder D, Byrne M, Cahn JY, Cairo M, Castillo P, Chhabra S, Diaz MA, Farhan S, Floisand Y, Frangoul HA, Gadalla SM, Gajewski J, Gale RP, Gandhi M, Gergis U, Hamilton BK, Hematti P, Hildebrandt GC, Kamble RT, Kanate AS, Khandelwal P, Lazaryn A, MacMillan M, Marks DI, Martino R, Mehta PA, Nishihori T, Olsson RF, Patel SS, Qayed M, Rangarajan HG, Reshef R, Ringden O, Savani BN, Schouten HC, Schultz KR, Seo S, Shaffer BC, Solh M, Teshima T, Urbano-Ispizua A, Verdonck LF, Vij R, Waller EK, William B, Wirk B, Yared JA, Yu LC, Arora M, Hashmi S. *Biol Blood Marrow Transplant.* 2019 May 11. pii: S1083-8791(19)30291-5.
 59. Alternative donor transplantation for acute myeloid leukemia in patients aged ≥ 50 years: young HLA-matched unrelated or haploidentical Donor? Perales MA, Tomlinson B, Zhang MJ, St Martin A, Beitinjaneh A, Gibson J, Hogan W, Kekre N, Lazarus H, Marks D, McGuirk J, Romee R, Solh M, Wagner JE, Weisdorf DJ, de Lima M, Eapen M. *Haematologica.* 2019 May 17. pii: haematol.2018.215202. doi: 10.3324/haematol.2018.215202. [Epub ahead of print]
 60. Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidentical Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor? Karam E, Laporte J, Solomon SR, Morris LE, Zhang X, Holland HK, Bashey A, Solh MM. *Biol Blood Marrow Transplant.* 2019 Jun 4. pii: S1083-8791(19)30356-8.

61. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Rashidi A, Hamadani M, Zhang MJ, Wang HL, Abdel-Azim H, Aljurf M, Assal A, Bajel A, Bashey A, Battiwalla M, Beitinjaneh AM, Bejanyan N, Bhatt VR, Bolaños-Meade J, Byrne M, Cahn JY, Cairo M, Ciurea S, Copelan E, Cutler C, Daly A, Diaz MA, Farhadfar N, Gale RP, Ganguly S, Grunwald MR, Hahn T, Hashmi S, Hildebrandt GC, Holland HK, Hossain N, Kanakry CG, Kharfan-Dabaja MA, Khera N, Koc Y, Lazarus HM, Lee JW, Maertens J, Martino R, McGuirk J, Munker R, Murthy HS, Nakamura R, Nathan S, Nishihori T, Palmisiano N, Patel S, Pidala J, Olin R, Olsson RF, Oran B, Ringden O, Rizzieri D, Rowe J, Savoie ML, Schultz KR, Seo S, Shaffer BC, Singh A, Solh M, Stockerl-Goldstein K, Verdonck LF, Wagner J, Waller EK, De Lima M, Sandmaier BM, Litzow M, Weisdorf D, Romee R, Saber W. *Blood Adv.* 2019 Jun 25;3(12):1826-1836
62. Fludarabine and Total Body Irradiation Conditioning Prior to Ablative Haploidentical Transplantation: Long-term Safety and Efficacy. Solomon SR, Solh M, Zhang X, Morris LE, Holland HK, Bashey A. *Biol Blood Marrow Transplant.* 2019 Jun 24. pii: S1083-8791(19)30381-7
63. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorrow ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR. *Clin Cancer Res.* 2019 Jun 28. doi: 10.1158/1078-0432.CCR-18-3988. [Epub ahead of print]
64. Real World outcomes of unselected elderly AML patients referred to a leukemia/hematopoietic cell transplant program. Solomon S, Solh M, Jackson K, Holland K, Bashey A, Morris L. *Bone Marrow transplantation* 2019, sept 16 (Epub ahead of print).
65. Maintenance tyrosine kinase inhibitors following auto-HCT for chronic myeloid leukemia: A CIBMTR study. Defilipp Z, Ancheta R, Liu Y, Solh M et al. *BBMT* 2019 Oct 25;S1083-8791(19)30674-3 [epub ahead of print]
66. A phase I study of ADCT 402 (Loncastuximab Tesirine), a Novel pyrolobenzodiazepine-based Antibody-Drug conjugate, in Relapsed refractory B cell Non-Hodgkin Lymphoma. Kahl BS, Hamadani M, Radford J, Carlo-Stella C, Solh M et al. *Clin can res.* 2019 Nov 4 [epub ahead of print]
67. Allogeneic transplantation in elderly patients ≥ 65 years with non-Hodgkin Lymphoma: a time trend analysis. Shah N, Ahn K, Litovich C, Solh M, Hamadani M. *Blood Cancer J.* 2019 Dec 3;9(12):97

68. Collection of Peripheral Blood Progenitor Cells in one Day is associated with Decreased donor toxicity compared to Two days in Unrelated donors. Hsu JW, Shaw BE et al Solh M. *BBMT* 2020 feb 20 Epub ahead of print.
69. Weighty Choices: Selecting optimal GCSF doses for stem cell mobilization to optimize yield. Farhadfar N, Hsu JW, solh M, Wingard JR et al. *Blood adv* 2020 feb 25;4(4):706-716
70. Alternative donor transplantation for acute myeloid leukemia in patients aged ≥ 50 years: young HLA-matched unrelated or haploidentical donor? Perales MA, Tomlinson B, Zhang MJ, St Martin A, Beitinjaneh A, Gibson J, Hogan W, Kekre N, Lazarus H, Marks D, McGuirk J, Romee R, **Solh M**, Wagner JE, Weisdorf DJ, de Lima M, Eapen M. *Haematologica*. 2020 Jan 31;105(2):407-413. doi: 10.3324/haematol.2018.215202. Print 2020
71. Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/- Idarubicin versus 3 + 7 (Anthracycline + Cytarabine). **Solh MM**, Solomon SR, Morris LE, Zhang X, Holland HK, Bashey A. *Leuk Res*. 2020 Jun;93:106318. doi: 10.1016/j.leukres.2020.106318. Epub 2020 Feb 14.
72. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, **Solh M**, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. *Leukemia*. 2020 Dec;34(12):3338-3347. doi: 10.1038/s41375-020-0830-0. Epub 2020 Apr 20.
73. Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysis. Farhadfar N, Murthy HS, Logan BR, Sees JA, Ayas M, Battiwalla M, Beitinjaneh AM, Chhabra S, Diaz MA, Engles K, Frangoul H, Ganguly S, Gergis U, Kamani NR, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Norkin M, O' Donnell PV, Olsson RF, Rossmann S, Savani BN, Schears R, Seo S, **Solh MM**, Spitzer T, Sugrue M, Yared JA, Linenberger M, Schwartz J, Pulsipher MA, Shah NN, Switzer GE, Confer DL, Shaw BE, Wingard JR. *Bone Marrow Transplant*. 2020 Nov;55(11):2121-2131. doi: 10.1038/s41409-020-0911-8. Epub 2020 Apr 30.
74. Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Agrawal V, Ahmed I, Al-Homsi AS, Aljurf M, Antin JH, Askar M, Auletta JJ, Bhatt VR, Chee L, Chhabra S, Daly A, DeFilipp Z, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Hogan WJ, Inamoto Y, Martino R, Majhail NS, Marks DI, Nishihori T, Olsson RF, Pawarode A, Diaz MA,

Prestidge T, Rangarajan HG, Ringden O, Saad A, Savani BN, Schoemans H, Seo S, Schultz KR, **Solh M**, Spitzer T, Storek J, Teshima T, Verdonck LF, Wirk B, Yared JA, Cahn JY, Weisdorf DJ. *J Clin Oncol*. 2020 Jun 20;38(18):2062-2076. doi: 10.1200/JCO.19.00396. Epub 2020 May 4.

75. Survival following allogeneic transplant in patients with myelofibrosis.

Gowin K, Ballen K, Ahn KW, Hu ZH, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, Gupta V, Hobbs G, Jain T, Kandarpa M, Komrokji R, Kuykendall AT, Lubber K, Masarova L, Michaelis LC, Patches S, Pariser AC, Rampal R, Stein B, Talpaz M, Verstovsek S, Wadleigh M, Agrawal V, Aljurf M, Angel Diaz M, Avalos BR, Bacher U, Bashey A, Beitinjaneh AM, Cerny J, Chhabra S, Copelan E, Cutler CS, DeFilipp Z, Gadalla SM, Ganguly S, Grunwald MR, Hashmi SK, Kharfan-Dabaja MA, Kindwall-Keller T, Kröger N, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Nathan S, Nishihori T, Olsson RF, Pawarode A, Rowe JM, Savani BN, Savoie ML, Seo S, **Solh M**, Tamari R, Verdonck LF, Yared JA, Alyea E, Popat U, Sobecks R, Scott BL, Nakamura R, Mesa R, Saber W. *Blood Adv*. 2020 May 12;4(9):1965-1973. doi: 10.1182/bloodadvances.2019001084.

76. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.

Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala J, Jagasia M, Pavletic S, Majhail NS, Weisdorf D, Abdel-Azim H, Agrawal V, Al-Homsi AS, Aljurf M, Askar M, Auletta JJ, Bashey A, Beitinjaneh A, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Cerny J, Chhabra S, Choe H, Ciurea S, Daly A, Perez MAD, Farhadfar N, Gadalla SM, Gale R, Ganguly S, Gergis U, Hanna R, Hematti P, Herzig R, Hildebrandt GC, Lad DP, Lee C, Lehmann L, Lekakis L, Kamble RT, Kharfan-Dabaja MA, Khandelwal P, Martino R, Murthy HS, Nishihori T, O'Brien TA, Olsson RF, Patel SS, Perales MA, Prestidge T, Qayed M, Romee R, Schoemans H, Seo S, Sharma A, **Solh M**, Strair R, Teshima T, Urbano-Ispizua A, Van der Poel M, Vij R, Wagner JL, William B, Wirk B, Yared JA, Spellman SR, Arora M, Hamilton BK. *Biol Blood Marrow Transplant*. 2020 Aug;26(8):1459-1468. doi: 10.1016/j.bbmt.2020.05.001. Epub 2020 May 17.

77. Correction: Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysis.

Farhadfar N, Murthy HS, Logan BR, Sees JA, Ayas M, Battiwalla M, Beitinjaneh AM, Chhabra S, Diaz MA, Engles K, Frangoul H, Ganguly S, Gergis U, Kamani NR, Kamble RT, Kasow KA, Lazarus HM, Liesveld JL, Norkin M, O' Donnell PV, Olsson RF, Rossmann S, Savani BN, Schears R, Seo S, **Solh MM**, Spitzer T, Sugrue M, Yared JA, Linenberger M, Schwartz J, Pulsipher MA, Shah NN, Switzer GE, Confer DL, Shaw BE, Wingard JR. *Bone Marrow Transplant*. 2020 Jun 8;10.1038/s41409-020-0963-9. doi: 10.1038/s41409-020-0963-9. Online ahead of print.

78. Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.

Goldberg AD, Atallah E, Rizzieri D, Walter RB, Chung KY, Spira A, Stock W, Tallman MS, Cruz HG, Boni J, Havenith KEG, Chao G, Feingold JM, Wuerthner J, **Solh M**. *Leuk Res*. 2020 Aug;95:106385. doi: 10.1016/j.leukres.2020.106385. Epub 2020 Jun 7.

79. Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant.

Solomon SR, Martin AS, Zhang MJ, Ballen K, Bashey A, Battiwalla M, Baxter-Lowe LA, Brunstein C, Chhabra S, Perez MAD, Fuchs EJ, Ganguly S, Hardy N, Hematti P, McGuirk J, Peres E, Ringden O, Rizzieri D, Romee R, **Solh M**, Szwajcer D, van der Poel M, Waller E, Williams BM, Eapen M. *Biol Blood Marrow Transplant*. 2020 Oct;26(10):1930-1936. doi: 10.1016/j.bbmt.2020.06.029. Epub 2020 Jul 7.

80. Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients.

Hu B, Lin X, Lee HC, Huang X, Tidwell RSS, Ahn KW, Hu ZH, Jabbour E, Verstovsek S, Ravandi F, Garcia-Manero G, Kharfan-Dabaja MA, Hossain NM, Marks DI, Kamble RT, Inamoto Y, Kindwall-Keller T, Saad A, Litzow MR, Savani BN, Hale GA, Bacher U, Gerds AT, Liesveld JL, Ustun C, Olsson RF, Daly A, Grunwald MR, **Solh M**, DeFilipp Z, Aljurf M, Wirk B, Akpek G, Nishihori T, Cerny J, Seo S, Hsu JW, Champlin R, de Lima M, Alyea E, Popat U, Sobecks R, Scott BL, Kantarjian H, Cortes J, Saber W. *Leuk Lymphoma*. 2020 Dec;61(12):2811-2820. doi: 10.1080/10428194.2020.1783444. Epub 2020 Jul 14.

81. Differences in Graft-versus-Host Disease Characteristics between Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors.

Solh MM, Baron J, Zhang X, Bashey A, Morris LE, Holland HK, Solomon SR. *Biol Blood Marrow Transplant*. 2020 Nov;26(11):2082-2088. doi: 10.1016/j.bbmt.2020.07.035. Epub 2020 Aug 1.

82. Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplant.

Solomon SR, **Solh M**, Zhang X, Brown S, Jackson K, Holland HK, Morris LE, Bashey A. *Blood Adv*. 2020 Aug 11;4(15):3669-3676. doi: 10.1182/bloodadvances.2020001958.

83. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes.

Nazha A, Hu ZH, Wang T, Lindsley RC, Abdel-Azim H, Aljurf M, Bacher U, Bashey A, Cahn JY, Cerny J, Copelan E, DeFilipp Z, Diaz MA, Farhadfar N, Gadalla SM, Gale RP, George B, Gergis U, Grunwald MR, Hamilton B, Hashmi S, Hildebrandt GC, Inamoto Y, Kalaycio M, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Liesveld JL, Litzow MR, Majhail NS, Murthy HS, Nathan S, Nishihori T, Pawarode A, Rizzieri D, Sabloff M, Savani BN, Schachter L, Schouten HC, Seo S, Shah NN, **Solh M**, Valcárcel D, Vij R, Warlick E, Wirk B, Wood WA, Yared JA, Alyea E, Popat U, Sobecks RM, Scott BL, Nakamura R, Saber W.

Biol Blood Marrow Transplant. 2020 Nov;26(11):2139-2146. doi: 10.1016/j.bbmt.2020.08.003. Epub 2020 Aug 8.

84. CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy.

Thapa B, Caimi PF, Ardeshta KM, **Solh M**, Carlo-Stella C, Kahl BS, Hamadani M. Blood Adv. 2020 Aug 25;4(16):3850-3852. doi: 10.1182/bloodadvances.2020002587.

85. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma.

Munshi PN, Vesole D, Jurczynszyn A, Zaucha JM, St Martin A, Davila O, Agrawal V, Badawy SM, Battiwalla M, Chhabra S, Copelan E, Kharfan-Dabaja MA, Farhadfar N, Ganguly S, Hashmi S, Krem MM, Lazarus HM, Malek E, Meehan K, Murthy HS, Nishihori T, Olin RL, Olsson RF, Schriber J, Seo S, Shah G, **Solh M**, Tay J, Kumar S, Qazilbash MH, Shah N, Hari PN, D'Souza A.

Cancer. 2020 Dec 1;126(23):5077-5087. doi: 10.1002/cncr.33171. Epub 2020 Sep 23.

86. African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States.

Badar T, Hari P, Dávila O, Fraser R, Wirk B, Dhakal B, Freytes CO, Rodriguez Valdes C, Lee C, Vesole DH, Malek E, Hildebrandt GC, Landau H, Murthy HS, Lazarus HM, Berdeja JG, Meehan KR, **Solh M**, Diaz MA, Kharfan-Dabaja MA, Callander NS, Farhadfar N, Bashir Q, Kamble RT, Vij R, Munker R, Kyle RA, Chhabra S, Hashmi S, Ganguly S, Jagannath S, Nishihori T, Nieto Y, Kumar S, Shah N, D'Souza A.

Cancer. 2020 Jan 1;127(1):82-92. doi: 10.1002/cncr.33208. Epub 2020 Sep 23.

87. Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS.

Gupta V, Kim S, Hu ZH, Liu Y, Aljurf M, Bacher U, Beitinjaneh A, Cahn JY, Cerny J, Copelan E, Gadalla SM, Gale RP, Ganguly S, George B, Gerds AT, Gergis U, Hamilton BK, Hashmi S, Hildebrandt GC, Kamble RT, Kindwall-Keller T, Lazarus HM, Liesveld JL, Litzow M, Maziarz RT, Nishihori T, Olsson RF, Rizzieri D, Savani BN, Seo S, **Solh M**, Szer J, Verdonck LF, Wirk B, Woolfrey A, Yared JA, Alyea EP, Popat UR, Sobecks RM, Scott BL, Nakamura R, Saber W. Blood Adv. 2020 Oct 13;4(19):4748-4757. doi: 10.1182/bloodadvances.2020002621.

88. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study.

Bejanyan N, Zhang M, Bo-Subait K, Brunstein C, Wang H, Warlick ED, Giralt S, Nishihori T, Martino R, Passweg J, Dias A, Copelan E, Hale G, Gale RP, **Solh M**, Kharfan-Dabaja MA, Diaz MA, Ganguly S, Gore S, Verdonck LF, Hossain NM, Kekre N, Savani B, Byrne M, Kanakry C, Cairo MS, Ciurea S, Schouten HC, Bredeson C, Munker R, Lazarus H, Cahn JY, van Der Poel M, Rizzieri D, Yared JA, Freytes C, Cerny J, Aljurf

M, Palmisiano ND, Pawarode A, Bacher VU, Grunwald MR, Nathan S, Wirk B, Hildebrandt GC, Seo S, Olsson RF, George B, de Lima M, Hourigan CS, Sandmaier BM, Litzow M, Kebriaei P, Saber W, Weisdorf D. *Biol Blood Marrow Transplant*. 2020 Oct 1:S1083-8791(20)30618-2. doi: 10.1016/j.bbmt.2020.09.026.

89. The Transplant Evaluation Rating Scale predicts overall survival after allogeneic hematopoietic stem cell transplantation.

Solh MM, Speckhart D, Solomon SR, Bashey A, Morris LE, Zhang X, Holland HK. *Blood Adv*. 2020 Oct 13;4(19):4812-4821. doi: 10.1182/bloodadvances.2020002204.

90. Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide.

Solomon SR, Aubrey MT, Zhang X, Jackson KC, Morris LE, Holland HK, **Solh MM**, Bashey A. *Blood Adv*. 2020 Oct 27;4(20):5311-5321. doi: 10.1182/bloodadvances.2020003110.

91. Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.

Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid EG, O'Connor OA, Feingold J, Ardeshta KM, Townsend WM, **Solh M**, Heffner LT, Ungar D, Wang L, Boni JP, Havenith K, Qin YG, Kahl B. *Blood*. 2020 Nov 19.2020007512. doi: 10.1182/blood.2020007512. Online ahead of print.

92. A phase II Trial of Melphalan Based Reduced-Intensity Conditioning for Transplantation of T-Replete HLA-Haploidentical Peripheral Blood Stem Cells with Posttransplant Cyclophosphamide in Patients with Hematological Malignancies.

Solh M, Solomon SR, Morris L, Holland K, Bashey A. *Advances in Haematology* vol 2021

93-Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. *Blood Adv*. 2021 Feb 23;5(4):975-983. doi: 10.1182/bloodadvances.2020003654. PMID: 33576783; PMCID: PMC7903230.

Grunwald MR, Zhang MJ, Elmariah H, Johnson MH, St Martin A, Bashey A, Battiwalla M, Bredeson CN, Copelan E, Cutler CS, George BR, Gupta V, Kanakry C, Mehta RS, Milano F, Mussetti A, Nakamura R, Nishihori T, Saber W, Solh M, Weisdorf DJ, Eapen M.

94-Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. *Leukemia*. 2021 Mar 29. doi: 10.1038/s41375-021-01233-1. Epub ahead of print. Erratum for: *Leukemia*. 2020 Dec;34(12):3338-3347. PMID: 33782538.

Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S,

Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A.

95- Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant.* 2021 May 20. doi: 10.1038/s41409-021-01353-3. Epub ahead of print. Erratum for: *Bone Marrow Transplant.* 2021 Apr 16;: PMID: 34017072. ercial ME, Wang HL, Zhang MJ, Saber W, de Lima M, Litzow M, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringdén O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM.

96- Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. *Lancet Oncol.* 2021 May 11:S1470-2045(21)00139-X. doi: 10.1016/S1470-2045(21)00139-X. Epub ahead of print. PMID: 33989558. Caimi PF, Ai W, Alderuccio JP, Ardeshtna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C.

97-Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. *JAMA Oncol.* 2021 May 6. doi: 10.1001/jamaoncol.2021.1074. Epub ahead of print. PMID: 33956047. Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S, Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, Hamadani M, Sauter CS.

98-Correction: Allogeneic transplantation in elderly patients ≥ 65 years with non-Hodgkin lymphoma: a time-trend analysis. *Blood Cancer J.* 2021 Apr 29;11(4):82. doi: 10.1038/s41408-021-00472-w. Erratum for: *Blood Cancer J.* 2019 Dec 3;9(12):97. PMID: 33927193; PMCID: PMC8085088.

99- Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant.* 2021 Apr 16. doi: 10.1038/s41409-021-01261-6. Epub ahead of print. Erratum in: *Bone Marrow Transplant.* 2021 May 20;: PMID: 33864019. ercial ME, Wang HL, Zhang MJ, Saber W, de Lima M, Litzow M, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V,

Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringdén O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM.

100-Efficacy and Safety Exposure–Response Analysis of Loncastuximab Tesirine in Patients with B-cell non-Hodgkin Lymphoma (AAPS J. 2021 Dec 10;24(1):11)

101- Open-Label Phase II prospective randomized controlled study of Romyelocel-L myeloid progenitor cells to reduce infection during induction chemotherapy for Acute Myeloid leukemia. Desai P, Brown J, Gill S, Solh MM, Akard LP, Hsu JW, Ustun C, Andreadis C, Frankfurt O, Foran JM, Lister J, Schiller GJ, Wieduwilt MJ, Pagel JM, Stiff PJ, Liu D, Khan I, Stock W, Kambhampati S, Tallman MS, Morris L, Edwards J, Pusic I, Kantarjian HM, Mamelok R, Wong A, Van Syoc R, Kellerman L, Panuganti S, Mandalam R, Abboud CN, Ravandi F. JCO 2021 oct 10;39(29): 3261-3272

102- An adapted European LeukemiaET genetic Risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis Bone Marrow Transplant. 2021 Sep 28. doi: 10.1038/s41409-021-01450-3. Online ahead of print.PMID: 34584240

103-Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous hematopoietic cell transplantation. Riedell PA, Hamadani M, Ahn KW, Litovich C, Brunstein CG, Cashen AF, Cohen JB, Epperla N, Hill BT, Im A, Inwards DJ, Lister J, McCarty JM, Ravi Kiran Pingali S, Shadman M, Shaughnessy P, Solh M, Stiff PJ, Vose JM, Kharfan-Dabaja MA, Herrera AF, Sauter CS, Smith SM. Br J Haematol. 2021 Sep 28. doi: 10.1111/bjh.17865. Online ahead of print.PMID: 34581433

104- Risk stratification at diagnosis predicts post-HCT outcomes in Intermediate, adverse-risk and KMT2A rearranged AML. Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, Zhang MJ, Bo-Subait K, Sanchez J, Wang HL, Aljurf M, Assal A, Bacher U, Badawy SM, Bejanyan N, Bhatt VR, Bredeson CN, Byrne M, Castillo P, Cerny J, Chhabra S, Ciurea SO, DeFilipp Z, Farhadfar N, Gadalla SM, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt GC, Kanakry CG, Kansagra A, Khimani F, Krem M, Lazarus HM, Liu H, Martino R, Michelis FV, Nathan S, Nishihori T, Olsson RF, Reshef R, Rizzieri D, Rowe JM, Savani BN, Seo S, Sharma A, Solh M, Ustun C, Verdonck LF, Hourigan CS, Sandmaier BM, Litzow MR, Kebriaei P, Weisdorf DJ, Zhang Y, Tallman MS, Saber W. Blood Adv. 2022 Jan 8;6(3): 828-847

105-Haploidentical vs Sibling, unrelated or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia Wieduwilt MJ, Metheny L, Zhang MJ, Wang HL, Estrada-Merly N, Marks DI, Al-Homsi AS, Muffly L, Chao NJ, Rizzieri D, Gale RP, Gadalla SM, Cairo MS,

Mussetti A, Gore SD, Bhatt VR, Patel SS, Michelis FV, Inamoto Y, Badawy SM, Copelan E, Palmisiano N, Kharfan-Dabaja MA, Lazarus HM, Ganguly S, Bredeson CN, Diaz Perez MA, Cassaday R, Savani BN, Ballen KK, Martino R, Wirk B, Bacher U, Aljurf M, Bashey A, Murthy HS, Yared JA, Aldoss I, Farhadfar N, Liu H, Abdel-Azim H, Waller EK, Solh M, Seftel M, van der Poel MWM, Grunwald MR, Liesveld JL, Kamble RT, McGuirk JP, Munker R, Cahn JY, Lee JW, Freytes CO, Krem M, Winestone LE, Gergis U, Nathan S, Olsson RF, Verdonck LF, Sharma A, Ringden O, Friend BD, Cerny J, Choe HK, Chhabra S, Nishihori T, Seo S, George B, Baxter-Lowe LA, Hildebrandt GC, de Lima M, Litzow MR, Kebriaei P, Hourigan CS, Abid MB, Weisdorf DJ, Saber W. Blood Adv 2022 jan 11;6(1): 339-357

106-Planned granulocyte-colony stimulating factor adversely impacts survival after allogeneic hematopoietic cell transplantation performed with thymoglobulin for myeloid malignancy Orfali N, Zhang MJ, Allbee-Johnson M, Boelens JJ, Artz AS, Brunstein CG, McNiece IK, Milano F, Abid MB, Chee L, Diaz MA, Grunwald MR, Hematti P, Hsu J, Lazarus HM, Munshi PN, Prestidge T, Ringden O, Rizzieri D, Riches ML, Seo S, Solh M, Solomon S, Szwajcer D, Yared J, Besien KV, Eapen M. Transplant Cell Ther. 2021 Dec; 27(12):993

107- ECP improves survival in steroid refractory GVHD. Farnham C, bashey A, solh m BMT under review

108-CK18-02: *The Mutational Landscape in Chronic Myelomonocytic Leukemia and its Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) Analysis.* We plan to submit this manuscript to Haematologica

109-The antiCD19 antibody drug immunoconjugate Loncastuximab achieves responses in DLBCL relapsing after antiCD19 CAR T cell therapy. Clin Lymphoma Myelo Leuk. 2021 Nov12: S2152-2650

110-Relapse and Disease free survival in patients with MDS undergoing allogeneic HCT using older matched sibling donors vs younger MUD donors. JAMA oncol 2022 jan 13:e216846

111-

Invited Book Chapters and Reviews

1. **Solh M**, Wadhwa P. Pulmonary complications of CLL. Pulmonary Involvement in Patients with Hematologic Malignancy. 2011
2. **Solh M**, Majhail N. Alternative Donor Transplantation for Adult Leukemia. Emerging Cancer Therapeutics V2 I2. Aug 2011.
3. **Solh M, Bashey A**. Graft versus Host Disease Prophylaxis. Clinical manual of Blood and Bone Marrow Transplant. 2015

Abstracts

1. **Solh M**. “Pancreatic cancer: Incidence And Mortality”, American University Of Beirut General Surgery Annual Meeting , Feb 2002
2. Danquah G, **Solh M**, Kolachalam R. “Internet use and its effect on surgical decision making.”, Detroit Surgical Association, Nov 2004
3. **Solh M**, Loboeki C, Mittal V, Dubay L. “Quinine inhibits cell growth in breast cancer cell lines.”, Providence Hospital resident research Day, April 2005
4. **Solh M**, Remine S, Dubay L. “Vitamin D3 analogues: antiproliferative effects in breast cancer.” American college of Surgeons Annual meeting, Michigan Chapter. May 2005
5. Chaiysate K, **Solh M**, Mittal V, Del Rosario G. “The Uncut roux-en-y with a jejunojejunostomy pouch. A new surgical technique after total gastrectomy.”, American College of surgeons Annual meeting, May 2005
6. **Solh M**. “Virtual Colonoscopy: An EBM review of the new look inside the colon.”, Wayne State University/DMC, EBM Research Day, Oct 2005
7. **Solh M**, Loboeki C, Mittal V, Dubay L. “Seocalcitol inhibits cell growth in breast cancer cell lines.” Sinai Grace research Day, April 2006
8. **Solh M.**, Bu-Ali H, Mittal V. “Synchronous versus metachronous breast cancer; characteristics of the second tumor” Wayne state University/DMC(Sinai-grace) research day, April 2006
9. **Solh M**, Loboeki C, Mittal V, Dubay L. “VitD3 induces differentiation in breast cancer independent of estrogen receptor”, ACP associates meeting, May 2006
10. **Solh M**, Loboeki C, Mittal V, Dubay L. Seocalcitol inhibits cell growth in breast cancer cell lines, ACP scientific meeting, Sept 2006
11. **Solh M**, Loboeki C, Dubay L Mittal V. Quinine inhibition of breast cancer is independent of ER expression. ACP associates Meeting, May 2008
12. **Solh M**. Chronic Lymphocytic Leukemia: New Risk Analysis. University of Minnesota, Department of Hematology Oncology Grand Rounds. April 2009
13. **Solh M**. Multiple Myeloma: Treatment of Patients not Eligible for Transplant. University of Minnesota, Department of Hematology Oncology Grand Rounds. Feb 2010
14. **Solh M**, Weisdorf D, Kaufman D. Extramedullary Relapse of AML after Allogeneic HCT: better Prognosis than Systemic Relapse. ASBMT Tandem Meeting. Feb 2011. BBMT 17(2) S256

15. **Solh M.** Myelodysplastic Syndrome: An Update. University of Minnesota, Department of Hematology and Oncology Grand Rounds. May 2011
16. **Solh M.** Role of Revlimid in MDS. Celgene Event. Orlando, Florida. May 2013
17. Jacobs M, **Solh M.** "GI manifestations of systemic mastocytosis.", International college of digestive surgery, Japan, Dec 2004
18. Chaiysate K, Del Rosario G, **Solh M**, Remine S, Mittal V. "Prognostic factors in primary adenocarcinoma of the small intestine.", 2005 resident research scholarship competition, International college of surgeons, Acapulco, Gro., Mexico, June 2005
19. **Solh M**, Dubay L, Loboeki C, Mittal V. "Novel therapies of Breast cancer.", American College of Surgeons 91st annual clinical congress, San Francisco, California, October 2005
20. **Solh M**, Kantarjian H, O'brien S, Cortes J, Ravandi F. "CNS leukemia in patient with CML after treatment with imatinib mesylate.", ASCO Annual meeting, June 2007
21. **Solh M**, C Loboeki, L Dubay, V Mittal. Vitamin D3 modulates cell growth and Differentiation in Breast cancer. AACR Breast Cancer Symposium. San Diego, October 2007
22. **Solh M**, S Jindani, G Krishnamoorthy. Clear cell sarcoma of the terminal ileum. American society of Gastroenterology. Annual Meeting Abstracts. October 2007
23. **Solh M**, K Chaiyasate, M Jacobs, V Mittal. Prognostic factors in primary adenocarcinoma of the small intestine. American Society of Clinical Oncology GI cancer Meeting Abstracts. January 2008
24. **Solh M**, C Loboeki, L Dubay, V Mittal. Seocalcitol and Vitamin D3 induce differentiation and inhibit cell growth in breast cancer. AACR annual meeting. San Diego, April 2008
25. **Solh M**, C Loboeki, L Dubay, V Mittal. Quinine induces differentiation in breast cancer cell lines. American Society of Breast Disease Annual Meeting Abstracts. April 2008
26. **Solh M**, H Bu-Ali, V Mittal. Synchronous and Metachronous Breast cancer. American Society of Clinical Oncology annual Meeting Abstracts. June 2008
27. **Solh M**, Majhail N, Weisdorf D. Late Onset non-infectious Pulmonary Complications Post Allogeneic Transplant. ASBMT Annual Meeting Abstracts. February 2010. BBMT Feb 2010; 16 (2): 226
28. **Solh M**, Burns L. A prognostic Index for Mechanically Ventilated HCT recipients. ASBMT Tandem Meeting. Feb 2011. BBMT 17(2) S274
29. Khaled Y, **Solh M**. Comparable Survival after unrelated and Related Allogeneic Stem Cell Transplantation performed at Community Cancer Centers. ASBMT Annual Tandem Meeting Abstracts. BBMT. Feb 2012, vol 8 (2) 348-349
30. Khaled Y, **Solh M** et al. Successful stem Cell Mobilization and Engraftment in Heavily pretreated Myeloma patients with prior high dose Melphalan and Autologous Stem cell Transplantation. ASBMT Tandem Meeting Abstracts. Feb 2012. BBMT. Feb 2012, vol 8 (2) ;300.
31. Oyer J, Copik A, Khaled Y, **Solh M**, Pacheco I, Hernandez B, Reddy V. Influence of IV Busulfan Conditioning on Immune Reconstitution and Donor Cell

- Chimerism After Allogeneic HCT. International Society For Cellular Therapy. June 2012
32. **Solh M**, Balls J, Smith T, Khaled Y. Leukocytosis post Engraftment is Associated with Increased Mortality among Allogeneic HCT recipients. ASBMT Tandem Meeting Abstracts. Feb 2013. BBMT 19(20) S308
 33. Khaled Y, Smith T, Fondaw M, **Solh M**. The Impact of Continuity of Care on Survival Outcomes after Allogeneic HCT. ASBMT Tandem Meeting Abstracts. Feb 2013. BBMT 19(2) S294
 34. Khaled Y, Fondaw M, Smith T, Balls J, **Solh M**. Plasma Cell CD20 Expression: Primary Aberrant expression or Receptor Upregulation. ASBMT Tandem Meeting Abstracts. Feb 2013 BBMT 19(2) S235
 35. Morrison V, **Solh M**. Older Age is a Risk factor for Hepes Zoster infection for Patients with Mantle Cell Lymphoma Receiving Bortezomib Therapy. Journal of Geriatric Oncology, 2013, Vol 3S, 62
 36. Matar A, **Solh M**, Copik A, Khaled Y. Relapse after allogeneic HCT for Acute Myelogenous Leukemia/MDS following intravenous Busulfan/Fludarabine Based conditioning: Outcomes and Monocyte chemo-attractant protein-1 (MCP-1) as a predictive marker of relapse. ASH annual Meeting. Dec 2013
 37. Oyer J, **Solh M**, Copik A. generation of clinical grade, highly cytotoxic NK cells using Feeder Cell Free, Particle-Based technology. ASH annual Meeting. Dec 2013
 38. **Solh M**, Khaled Y, Copik A. Effect of Plerixafor mobilization on immune reconstitution post high dose chemotherapy and autologous stem cell transplantation. ASH Annual Meeting 2013
 39. Khaled Y, **Solh M**, Matar A. Relapse after Allogeneic HCT for AML/MDS following intravenous Busulfan Plus fludarabine based conditioning: outcomes and monocytes chemoattractant protein -1. ASBMT Annual meeting 2014. Oral Session
 40. Smith T, Fondaaw M, Khaled Y, **Solh M**. Improving hospital consumer assessment of healthcare providers and systems scores in bone marrow transplant inpatient setting. ASBMT Annual Meeting. 2014 Poster Session
 41. Sauvai Chang-Fong, **Solh M**. Performance Validation of revolution centrifugal force (RCF) for plasma depletion on hematopoietic progenitor cell apheresis product using Sorvall ST40R Centrifuge. ASBMT Annual Meeting 2014 Poster Session
 42. **Solh M**, Copik A, Khaled Y. Effect of mobilization on immune reconstitution post high dose chemotherapy and autologous HCT. ASBMT Annual Meeting 2014 Poster Session
 43. Matar A, Fondaw M, **Solh M**, Khaled Y. Low Dose thymoglobulin result in improved outcomes after allogeneic unrelated HCT for patients with AML/MDS after intravenous busulfan. ASBMT Annual Meeting 2014 Poster Session
 44. **Solh M**, Smith T, Khaled Y. Guillian-Barre Syndrome (GBS) Post Adult Cord blood transplantation in a patient with CLL. ASBMT annual meeting 2014 Poster session.

45. Oyer J, Pandey V, **Solh M**, Copik A. In Vitro Preactivation of PBMCs with PM-mb21-41BBL Particles Stimulates in vivo expansion of NK cells Under Low IL-2 in NSG mice. ASH annual Meeting 2014 Poster Session.
46. **Solh M**, Rathmann K, Copik A, Khaled Y. Method of Mobilization : Implication on Cell subsets in the Graft and Immune Reconstitution Post Autologous Hematopoietic Cell Transplantation. ASH Annual Meeting 2014 Poster Session
47. Chang S, Rathmann K, Copik A, **Solh M**. Effect of Graft and Early Posttransplantation Invariant Killer T cells on disease relapse post allogeneic HCT. ASH Annual Meeting 2014 Poster Session.
48. **Solh M**, Morgan S, Mc Cullough J, Weisdorf D. Do blood transfusions cause pulmonary complications following hematopoietic cell transplantation? ASH annual Meeting 2014 Poster Session
49. Bashey A, Zhang X, Jackson K, Brown S, **Solh M**, Morris LE, Holland HK, Solomon S. Non-Inferior survival of black versus white patients and superior outcomes for black females compared to other race/gender groups following allogeneic transplantation for hematologic malignancy: A single center multivariable analysis of 475 allografted patients. 57th Annual ASH Meeting. Abstract # 401- Oral Presentation, December 2015
50. Bashey A, Zhang X, Jackson K, Brown S, **Solh M**, Morris LE, Holland HK, Solomon S. Lineage specific chimerism analysis reveals that mixed donor T-cell chimerism is common in the early post-transplant period following myeloablative allotransplants from HLA-matched but not HLA-haploidentical donors: A multivariable analysis of allografted patients from a single center. 57th Annual ASH Meeting. Abstract # 4327 – Poster Session, December 2015
51. Solomon S, Sizemore C, Zhang X, **Solh M**, Morris LE, Holland HK, Bashey A. Disease risk index is the major predictor of outcome following myeloablative haploidentical hematopoietic stem cell transplantation (haplo-HSCT) and post-transplant cyclophosphamide (PT/Cy). 57th Annual ASH Meeting. Abstract # 2010 – Poster Session, December 2015
52. Solomon S, Sizemore C, Zhang X, Connor K, **Solh M**, Holland HK, Morris LE, Bashey A. Disease risk and host factors, not transplant type, predict outcome following allogeneic hematopoietic stem cell transplantation for acute leukemia. 57th Annual ASH Meeting. Abstract # 4372 – Poster Session, December 2015
53. Solomon S, Sanacore M, Zhang X, Connor K, **Solh M**, Bashey A, Morris LE, Holland HK. Targeted oral busulfan (BU/cyclophosphamide (CY)/VP-16 and autologous stem cell transplant (ASCT) for Hodgkin's (HL) and non-hodgkin's lymphoma (NHL) results in excellent 5-year survival and low treatment related mortality: Ten-year single center experience of 246 consecutively treated patients. 57th Annual ASH Meeting. Abstract # 3185 – Poster Session, December 2015
54. Solomon S, Sanacore M, Zhang X, Connor K, **Solh M**, Morris LE, Holland HK, Bashey A. In vivo T cell depletion with thymoglobulin of alemtuzumab is associated with worse outcome following allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients transplanted in remission. 57th Annual ASH Meeting. Abstract # 3115 – Poster Session, December 2015
55. **Solh M**, Zhang X, Brown S, Morris LE, Holland HK, Solomon S, Bashey A. Lower use of DLI post relapse of malignancy may result in shorter post-relapse

- survival (PRS) in patients undergoing T cell replete haploidentical donor transplantation (HIDT) versus matched related (MRD) or matched unrelated donor (MUD) hematopoietic cell transplantation (HCT). 57th Annual ASH Meeting. Abstract # 1967 – Poster Session, December 2015
56. **Solh M**, Connor K, Zhang X, Brown S, Morris LE, Holland HK, Bashey A, Solomon S. T cell replete HLA- haploidentical donor transplantation (HIDT) with post-transplant cylophosphamide (pTcy) is an effective salvage for patients relapsing after a matched sibling or a matched unrelated donor transplantation. 57th Annual ASH Meeting. Abstract # 1960 – Poster Session, December 2015
 57. **Solh M**, Zhang X, Connor K, Brown S, Holland HK, Morris LE, Solomon S. Factors predicting GVHD free, relapse free survival (GRFS) after allogeneic hematopoietic cell transplantation: a multivariable analysis of 531 allografts from single center. 57th Annual ASH Meeting. Abstract # 2028- Poster Session
 58. Khaled Y, Patel R, Ahmed W, Mori S, **Solh M**. Thymoglobulin after matched unrelated hematopoietic stem cell transplantation (HCT) in AML/MDS results in improved outcomes comparable to matched related HCT. ASBMT Tandem Meeting. Poster Session, Feb. 2016
 59. Atallah E, Chung K, Rizzieri D, Spira A, Stock W, Jain N, Walter R, Mawad R, Khoury H, **Solh M**, Feingold J, Tallman M. A phase 1, open-label dose-escalation, multicenter study to evaluate the tolerability, safety, pharmacokinetics, and activity of ADCT-301 in patients with relapsed or refractory CD-25-positive acute lymphoblastic leukemia. 2016 ASCO Meeting. Abstract TPS7071 Poster Session
 60. Solomon S, Sizemore C, Ridgeway M, Zhang X, **Solh M**, Morris LE, Holland HK, Bashey A. Current graft-versus-host-disease (GVHD), relapse-free Survival – a novel, dynamic composite endpoint to better define effectiveness following allogeneic hematopoietic cell transplantation. 58th Annual ASH Meeting. Abstract # 1170, Oral Presentation
 61. **Solh M**, Bashey A, Solomon S, Morris LE, Zhang X, Brown S, Holland HK. Excellent long term survival among patients who are disease-free at one year after allogeneic hematopoietic cell transplantation: A single center analysis of 667 consecutive patients. 58th Annual ASH Meeting. Abstract # 4622, Poster, December 2016
 62. **Solh M**, Bashey A, Solomon S, Morris LE, Holland HK, Zhang X. Outcomes for allogeneic hematopoietic cell transplantation for AML and high grade MDS in older adults in the era of T-replete haploidentical donor grafts. A single center multivariate analysis. 58th Annual ASH Meeting. Abstract # 4665, Poster, December 2016
 63. **Solh M**, Morris LE, Holland HK, Solomon S, Brown S, Bashey A. Donor type and disease risk predict the success of allogeneic hematopoietic cell transplantation (HCT): A single center analysis of 613 adult HCT recipients u using a modified composite endpoint. 58th Annual ASH Meeting. Abstract # 4574, Poster, December 2016
 64. Bashey A, Zhang X, Brown S, Jackson K, **Solh M**, Lawrence M, Holland HK, Solomon S. Myeloablative allogeneic hematopoietic cell transplantation performed without routine inpatient admission: A single center experience of 462

- ients. *58th Annual ASH Meeting*. Abstract # 661, Oral Presentation, December 2016
65. Bashey A, Zhang M, Mccurdy S, Ciurea S, St. Martin A, Anasetti C, Argall T, Fasan O, Gaballa S, Hamandani M, Malki M, Munshi P, Nakamura R, O'donnell Raj K, Rocha V, Romee R, Rowley S, Salit R, **Solh M**, Soiffer R, Wingard J, Weisdorf D, Horowitz M, Fuchs E, Eapen M. Comparison of peripheral blood stem cells (PBSC) to bone marrow (BM) for T-replete HLA-Haploidentical donor transplantation using post-transplant cyclophosphamide. *58th Annual ASH Meeting*. Abstract # 683, Oral Presentation, December 2016
 66. Sanacore M, Eaton S, Morris LE, Solomon S, Bashey A, **Solh M**, Holland HK. Prospective assessment of diagnostic infectious disease molecular PCR testing with early fiber-optic bronchoscopy (FOB) in the evaluation of new pulmonary infiltrates in hematopoietic stem cell transplantation (HSCT) and acute leukemia (AL) patients (pts). *Tandem Meeting*. Oral Presentation, abstract # 9355, February 2017
 67. **Solh M**, Dickhaus E, Gruber L, Bashey A, Solomon S, Holland HK, Morris LE, Brown S. Fevers post infusion of T-cell replete HLA mismatched haploidentical hematopoietic stem cells. *Tandem Meeting*. Oral Presentation, abstract # 8901, February 2017
 68. **Solh M**, Gorgeis J, Sizemore C, Solomon S, Holland HK, Morris LE, Bashey A. Nitazoxanide is effective therapy for norovirus gastroenteritis after hematopoietic stem cell transplantation. *Tandem Meeting*. Poster, abstract # 348, February 2017
 69. Solomon S, Aubrey, Zhang X, Freed B, Piluso A, Connor K, Brown S, Holland HK, Morris LE, **Solh M**, Bashey A. Impact of donor characteristics on transplant outcome following haploidentical hematopoietic cell transplantation utilizing post-transplant cyclophosphamide: Improving donor selection criteria. *Tandem Meeting*. Poster, abstract #309, February 2017
 70. LaPorte J, Leon K, Zhang X, Morris LE, Solomon S, Holland HK, **Solh M**, Bashey A. A unique schedule of Palonosetron, Ondansetron and Dexamethasone for the prevention of delayed nausea and vomiting in patients receiving myeloablative chemotherapy. *Tandem Meeting*. Poster, abstract # 230, February 2017
 71. Solomon S, Aubrey M, Zhang X, Piluso A, Freed B, Brown S, Jackson K, **Solh M**, Morris LE, Holland HK, Bashey A. Selecting the best donor for T cell-replete haploidentical transplantation: Importance of HLA disparity, NK alloreactivity, and other clinical variables. *59th Annual ASH Meeting*. Abstract # 670. Oral Presentation. December 2017
 72. Bashey A, Zhang X, Brown S, Jackson K, Morris LE, Holland HK, **Solh M**. Identifying risk factors for acute and chronic graft versus host disease in T-replete HLA-haploidentical hematopoietic cell transplantation with post transplant cyclophosphamide. *59th Annual ASH Meeting*. Abstract # 1977. Poster. December 2017
 73. **Solh M**, Zhang X, Solomon S, Morris LE, Holland HK, Bashey A. Who is a better donor for recipients of allogeneic hematopoietic cell transplantation: A young HLA haploidentical relative or an older fully matched HLA-matched

- sibling or unrelated volunteer? *59th Annual Ash Meeting*. Abstract # 4604. Poster. December 2017
74. Kahl B, Hamadani M, Caimi P, Carlo-Stella C, Reid E, Feingold J, Ardesna K, Radford J, **Solh M**, Hung K-Y, Heffner L, He S, Boni J, O'connor O. Early results from the first in human clinical trial of ADCT-402 (Loncastuximab Tesirine), a novel pyrrolobenzodiazepine based antibody drug conjugate, in relapsed/refractory B-cell lineage non-hodgkin lymphoma. *59th Annual Ash Meeting*. Abstract # 402.Oral Presentation. December 2017
 75. Goldberg, A, Tallman M, **Solh M**, Ungar D, Rizzieri D, Walter R, Spira A, Chung K-Y, Stock W, He S, Boni J, Atallah E. Interim data from a phase 1 study evaluating pyrrolobenzodiazepine-based antibody drug conjugate ADCT-301 Camidanlumab Tesirine) for relapsed or refractory CD25-positive acute leukemia. *59th Annual ASH Meeting*. Abstract # 302. Poster. December 2017
 76. Sizemore C, Ridgeway M, Zhang X, Morris LE, Holland HK, **Solh M**, Bashey A, Solomon S. Rituximab based on first line treatment for chronic GVHD following allogeneic transplant: Single center analysis of 95 patients. 2018 BMT Tandem Meeting. Abstract # 224. Poster. February 2018
 77. Kronenberg O, Miller J, Sizemore C, Hanik M, Brown S, Bashey A, Solomon S, Morris LE, Holland HK, **Solh M**. A prospective pilot study of implementing a sepsis management protocol among adult hematopoietic stem cell transplant recipients. 2018 BMT Tandem Meeting. Abstract # 564. Poster. February 2018
 78. **Solh M**, Zhang X, Brown S, Morris LE, Holland HK, Bashey A, Solomon S. The dilemma of conditioning intensity: When does myeloablative conditioning improve outcomes for allogeneic hematopoietic cell transplantation? 2018 BMT Tandem Meeting. Abstract # 68. Oral Presentation. February 2018
 79. Abboud C, Akard L, Adreadis C, Desai P, Foran J, Frankfurt O, Gill S, Hsu J, Pagel J, schiller G, **Solh M**, Ustun C, Wieduwilt M, Wong A, Van Syoc R, Ravandi F. A randomized open label exploratory controlled trial of CLT-008 myeloid progenitor cells (MPC) to decrease infections during induction for AML. ASCO 2018 Chicago. Poster.
 80. Miguel-Angel Perales, Benjamin Tomlinson, Mei-Jie Zhang, Andrew St. Martin, Hillard Lazarus, David Marks, Rizwan Romee, **Melhem Solh**, John Wagner, Daniel Weisdorf, Marcos de Lima, Mary Eapen. Outcomes after T-Replete HLA-Haploidentical Transplantation Using Post-Transplant Cyclophosphamide Compared to Matched Unrelated Donor Transplantation for Acute Myeloid Leukemia in Remission in Older Adults. EBMT 2018 Oral presentation.
 81. Desai P, AkardL, Andreadis C, Foran J, Frankfurt O, HSU J, Gill S, Lister J, Pagel J, Schiller G, **Solh M**, Ustun C, Brown J, Wong A, Kellerman L, Panuganti S, Solish S, Mandalam R, Mamelok R, Abboud C. Decreased Incidence of infection, use of antibacterials and days in hospital after administration of CLT-008 myeloid progenitor cells to subjects receiving AML induction therapy: Phase 2 study results. EHA meeting 2018. Oral presentation.
 82. The Choice of Induction Regimen Affects Post Remission Survival of Acute Myelogenous Leukemia (AML) Patients with Intermediate or Poor Risk DiseaseMelhem Solh, Scott R Solomon, Lawrence E Morris, H.

- Kent Holland, Xu Zhang and Asad Bashey Blood 2018 132:82;(ASH oral Presentation)
83. Long-Term Follow-up of Myeloablative Haploidentical (HID) Peripheral Blood Stem Cell Transplantation and Post-Transplant Cyclophosphamide (PTCy) Following Fludarabine and Total Body Irradiation (TBI) .Scott R Solomon, Xu Zhang, Melhem Solh, Lawrence E Morris, H. Kent Holland and Asad Bashey Blood 2018 132:3368. ASH 2018 Poster
 84. Transplant Rates and Outcomes of Young Acute Myeloid Leukemia (AML) Patients with Intermediate and Poor Risk Disease Referred to a Coordinated Acute Leukemia and Hematopoietic Stem Cell Transplant (HSCT) Program Melhem Solh, Xu Zhang, Asad Bashey, Lawrence E Morris, Zain Bashey, H. Kent Holland and Scott R Solomon Blood 2018 132:4797;
 85. Treatment Patterns and Outcomes of Unselected Elderly Acute Myeloid Leukemia (AML) Patients Referred to a Combined Acute Leukemia and Hematopoietic Stem Cell Transplant (HSCT) Program Scott R Solomon, Katelin C Jackson, Xu Zhang, Melhem Solh, Asad Bashey, H. Kent Holland and Lawrence E Morris Blood 2018 132:2675
 86. Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study Paolo Caimi, Brad S. Kahl, Mehdi Hamadani, Carmelo Carlo Stella, Shui He, David Ungar, Jay Feingold, Kirit M. Ardesna, John Radford, Melhem Solh, Leonard Heffner and Owen A. O'Connor Blood 2018 132:2874
 87. Class II HLA Epitope Level Mismatch Can Predict Chronic Graft-Versus-Host Disease and Survival Following Haploidentical Transplant Using Post-Transplant Cyclophosphamide Scott R Solomon, Michael T Aubrey, Cheri Anobile, Xu Zhang, Brian M Freed, Lawrence E Morris, H. Kent Holland, Melhem Solh and Asad Bashey Blood 2018 132:311;
 88. Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. John Radford, Brad S. Kahl, Mehdi Hamadani, Carmelo Carlo-Stella, Paolo Caimi, Kirit M. Ardesna, Jay Feingold, Shui He, Erin Reid, Melhem Solh, Ki-Young Chung, Leonard Heffner, David Ungar and Owen A. O'Connor Blood 2018 132:398;
 89. Evaluation of Romylocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy. Farhad Ravandi, Camille N Abboud, Luke

Paul Akard, Saarl. Gill, JackW. Hsu, Suman Kambhampati, Irum Khan, Delong Liu, Wendy Stock, Janice W Brown, Asad Bashey, Gautam Borthakur, Courtney D. DiNardo, H. Kent Holland, Tapan M. Kadia, Hagop M. Kantarjian, Lawrence E Morris, Scott R Solomon, RichardDavid Mamelok, Swapna Panuganti, Rod VanSyoc, Alicia Wong, Deborah Zimmerman and Melhem Solh *Blood* 2018 132:1407;

90. Bashey A, Zhang X, Morris LE, Holland HK, Solh M, Solomon S. Improved Survival of Patients diagnosed with Severe (Grade 3-4) Acute GVHD or Severe NIH Grade Chronic GVHD in the Current Era Compared to Historic Controls, *ASH 2019 Meeting*- Abstract# 123230.
91. Bashey A, Zhang X, Morris LE, Holland HK, Solomon S., Solh M, Improved Survival in Patients Who Undergo Relapse of Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation, *ASH 2019 Meeting*
92. Bashey A, Zhang X, Morris LE, Holland HK, Solh M, Solomon S., Impact of Patient Race in Comparison of Outcomes Following T-Replete Haploidentical Donor Allografts using Post-Transplant Cyclophosphamide Versus HLA-Identical Sibling Allografts for Hematologic Malignancy-, *ASH 2019 Meeting*, Abstract# 123545
93. Solomon S., Bashey A, Zhang X, Brown S, Jackson K, Morris LE, Holland HK, Solh M, Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post Transplant Cyclophosphamide- *ASH 2019 Meeting*, Abstract#124354
94. Solh M, Solomon S., Holland HK, Morris LE, Bashey A, A Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post Infusion of T-Replete Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells with Post Transplant Cyclophosphamide, *ASH 2019 Meeting*
95. Solh M, Solomon S, Zhang X, Holland HK, Morris LE, Bashey A, A Phase II Trial of Melphalan Based Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients with Hematologic Malignancies, *ASH 2019 Meeting*
96. Solh M, Speckhart, D, Zhang X, Bashey A, Solomon S, Morris LE, Holland HK, A Psychological and Social Factors are a Strong Predictor of Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Independent of Disease Risk and Morbidity Score, *ASH 2019 Meeting*
97. Solh M, Zhang X, Bashey A, Morris LE, Holland HK, Solomon S, Graft Versus Host Disease (GVHD) after HLA-Mismatched Haploidentical Transplantation with Post-Transplant Cyclophosphamide Compared to Matched Unrelated Donor: Incidence, Distribution and Response to Therapy, *ASH 2019 Meeting*
98. Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolbenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Carlo-Stella C, Zinzani P, Kahl B, Caimi P, Solh M et al. *ASH 2019 Oral presentation*

99. Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome. ASH 2019 Poster
100. Allogeneic Transplantation for MDS in adults over 50 years old using reduced intensity/nonmyeloablative conditioning: Haploidentical relative versus matched unrelated donors. Grunwald M, Zhang M, Elmariah H, Johnson M, Solh M et al. ASH 2019 Poster
101. Evaluation of Tacrolimus Levels and Risk of Graft-Versus-Host Disease, Relapse and Non-Relapse Mortality after Haploidentical Transplantation with Post-Transplant Cyclophosphamide. Tempte M, Zhang X, Solh M, Solomon S et al. TCT Annual meeting 2020 Poster.
102. Initial Results of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Carlo Stella C, Zinzani P, Solh M et al. EHA Annual Meeting 2020
103. Integrated population modeling of loncastuximab tesirine (Lonca) exposure in B cell NHL. AACR 2020
104. Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), Alexander M. Lesokhin, MD¹, Moshe Y. Levy, MD², Andrew P. Dalovisio, MD³, Nizar Bahlis, MD⁴, **Melhem Solh, MD⁵**, Michael Sebag, MD, PhD, FRCPC⁶, Andrzej Jakubowiak, MD, PhD⁷, Yogesh S. Jethava, MBBS, MD, FRCPath, MRCP⁸, Caitlin L. Costello, MD⁹, Michael P. Chu, MD¹⁰, Michael R. Savona, MD¹¹, Cristina Gasparetto, MD¹², Suzanne Trudel, MD, MSC, FRCPC¹³, Jeffrey Chou, MD, PhD^{14*}, Chandrasekhar Udata, PhD^{15*}, Cynthia Basu, PhD^{15*}, Heike I. Krupka, PhD, PMP^{14*} and Noopur S. Raje, MD¹⁶ ASH 2020
105. Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Paolo F Caimi^{1*}, Weiyun Z. Ai², Juan Pablo Alderuccio, MD³, Kirit M. Ardesna⁴, Mehdi Hamadani, MD⁵, Brian T. Hess, MD⁶, Brad S. Kahl, MD⁷, John A. Radford, MD, FMedSci^{8*}, **Melhem Solh, MD⁹**, Anastasios Stathis, MD^{10*}, Pier Luigi Zinzani, MD¹¹, Jay Feingold^{12*}, David Ungar¹³, Yajuan Qin^{13*}, Shui He^{13*} and Carmelo Carlo-Stella, MD¹⁴ ASH 2020
106. Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome, Alice S. Mims, MD¹, **Melhem Solh, MD²**, Uma Borate³, Naveen Pemmaraju, MD⁴, Gautam Borthakur, MD⁵, Gail J. Roboz, MD⁶, Ben Powell, PhD^{7*}, Paul Severson, PhD^{7*}, Bernice Matusow^{7*},

Jason Halladay, PhD^{7*}, Ching Hsu, PhD^{8*}, Paul Watkins^{7*}, Chao Zhang, PhD^{7*}, Jackie M. Walling, PhD, MD⁷, Athanasios C. Tsiatis, MD⁷ and Amy E. DeZern, MD ASH 2020

107. CD34+ Selected Hematopoietic Cell Boosts (HCB) for Treatment of Refractory Cytopenia Following T-Replete HLA-Haploidentical Transplantation, **Asad Bashey, MD, PhD¹**, Xu Zhang, PhD^{2*}, Lawrence E Morris, MD¹, H. Kent Holland, MD¹, Scott R. Solomon, MD³ and Melhem Solh, MD¹ ASH 2020

108- Integrated population modeling of loncastuximab tesirine (Lonca) exposure in B-cell non-Hodgkin lymphoma (B-NHL) AACR 2021

109-LOTIS 2 follow-up analysis: Updated results from a Phase 2 study of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma” has been submitted to the Pan Pacific Lymphoma Conference 2021.

110- LOTIS 2 Follow-Up Analysis: Updated Results From A Phase 2 Study Of Loncastuximab Tesirine (Lonca) In Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Brad S. Kahl¹, Mehdi Hamadani², Paolo F. Caimi³, Carmelo Carlo-Stella⁴, Weiyun Ai⁵, Juan Pablo Alderuccio⁶, Kirit M. Ardeschna⁷, Brian Hess⁸, John Radford⁹, Melhem Solh¹⁰, Anastasios Stathis¹¹, Jay Feingold¹², David Ungar¹², Yajuan Qin¹², Shui He¹², Pier Luigi Zinzani¹³ · SOHO meeting 2021

111-Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM). Blahis N, Solh M et al. ASCO meeting June 2021 Oral Presentation

112-Duration of response to loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma by demographic and clinical characteristics: Subgroup analysis from LOTIS 2’ ASCO 2021 Poster

113-Title: MAGNETISMM-1: PHASE 1 STUDY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) TARGETED CD3-ENGAGING BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (MM). Oral Presentation EHA Annual Meeting, June 11 2021

114-Duration of response to loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma by demographic and clinical characteristics: Subgroup analysis from LOTIS 2’ poster presentation at EHA June 11, 2021

115-ADCT-402-201 updated analysis abstract entitled “LOTIS 2 follow-up analysis: Updated results from a Phase 2 study of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma”. ICML 2021 ePoster

116-Incidence, onset, and management of myelosuppression in patients treated with loncastuximab tesirine for R/R DLBCL in a pooled safety analysis" (In Process SOHO 2021)

117-Incidence, onset, and management of edema and effusion in patients treated with loncastuximab tesirine for R/R DLBCL in the LOTIS clinical trial program" (in process SOHO 2021)

118-*MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM). 18th international Myeloma Workshop*

119- Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen(BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma.
HEMO Brazilian Congress of Hematology, Hemotherapy and Cell Therapy (HEMO) October 27 – 30, 2021,

120-Optimizing Donor Selection for Haploidentical Transplantation Utilizing the Four-Group T Cell Epitope (TCE-4) Algorithm for Prediction of HLA-DPB1 Non-Permissive Mismatches Oral ASH 2021

121-: Recipient HLA-B Leader Genotype, and Its Relationship to Total KIR Missing Ligand, Informs Relapse and Survival Following Haploidentical Transplantation Using Post-Transplant Cyclophosphamide oral ASH 2021

122-Post-Relapse Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post Transplant Cyclophosphamide (PTCY): Potential Impact of DLI Post-Relapse poster ASH 2021

123-Impact of Choice of Induction Regimen on Overall Survival and Post-Remission Survival Among Older Adults with Acute Myeloid Leukemia Poster ASH 2021

124-The Intensity of the Induction Regimen Does Not Affect Post-Transplant Survival Among Patients with Newly Diagnosed Mantle Cell Lymphoma poster ASH 2021

125-Barriers to and Results of Allogeneic Hematopoietic Transplantation for Adult Patients with Sickle Cell Disease: An Analysis of Referrals and Transplants Performed at a Single Center in the Era of Haploidentical Donor Use poster ASH 2021

126-High-Dose Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Conditioning Prior to Autologous Transplantation for Patients with Multiple Myeloma: Results of a Prospective Phase II Trial poster ASH 2021

127-Final Results of a Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome poster ASH 2021

128-Clinical characteristics and response of patients with relapsed and refractory HGBCL treated with loncastuximab tesirine in the LOTIS 2 clinical trial poster ASH 2021

129-Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetism-1 oral ASH 2021

130-The anti CD-19 antibody-drug conjugate loncastuximab tesirine achieved responses in patients with Diffuse large B-cell Lymphoma who relapsed after anti CD19 CAR -T cell therapy. poster ASH 2021

131-Let's Get Serial: Detection and Monitoring of Mucormycosis in Hematopoietic Stem Cell Transplant Recipients with the Karius Test™. ASTCT 2022

132-Effect of Early Post-Transplant Respiratory Viral Infections on Graft-Versus-Host Disease (GVHD) and Other Transplant Outcomes. ASTCT 2022

133-Outcomes of MDS and AML Patients with TP53 Gene Mutation Receiving Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). ASTCT 2022

134-Allogeneic Hematopoietic Cell Transplantation (HCT) for Adult Patients with Acute Lymphoblastic Leukemia: Impact of Timely Transplantation on Survival Outcomes. ASTCT 2022

135-Post-Relapse Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post Transplant Cyclophosphamide (PTCY): Potential Impact of DLI Post-Relapse. ASTCT 2022

136-Onset, duration, and management of edema and effusion in patients treated with loncastuximab tesirine for R/R DLBCL: updated results from the LOTIS-2 clinical trial” has been submitted to ONS 2022.

137- Disease-Specific Pathways for NK Cell Alloreactivity Informs Relapse Risk after Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide: Relative Effect of Recipient HLA-C-Group KIR Ligand and HLA-B-Leader Allotype. ASTCT 2022

138- Safety and Anti-Tumor activity of Plamotamab (XmAb13676), an anti-CD20 x anti-CD3 Bispecific antibody, in subjects with relapsed/refractory Non-Hodgkin’s Lymphoma. Poster ASH 2021

139-Elrantamab, a BCMA targeted T-cell redirecting immunotherapy, for patients with R/R MM: Uppdated results from MagnetismMM_1. ASCO 2022

